(Geared toward health professionals) Newly identified biomarkers may be able to distinguish fatal from nonfatal Ebola infections, ultimately enabling clinicians to prioritize scarce treatment resources, researchers suggest. Dr. Yoshihiro Kawaoka of the University of Wisconsin-Madison and colleagues used a technique called multi-platform ’omics (multi-omics) to analyze and compare 29 samples of peripheral blood mononuclear cells taken at initial diagnosis from 11 patients who survived the 2014 Ebola outbreak in Sierra Leone and nine samples from nine patients who died.
Office of Strategic Communication